Bibliography
- Lambert P. Antibiotic resistance: a challenge for the industry. Ind Pharm 2006;10:6-7[Cited 3 Jan 2009]. Available from: www.industrialpharmacy.com
- Charles Darwin theory of evolution. Brief summary. On truth and reality, 2009. Available from: http://www.spaceandmotion.com/Charles-Darwin-Theory-Evolution.htm [Cited 15 Jan 2009]
- Darwin's theory of evolution: a theory in crisis. All about science, 2008. Available from: http://www.darwins-theory-of-evolution.com/ [Cited 25 Jan 2009]
- Greenwood D, Finch R, Davey P, et al. Antimicrobial chemotherapy. Fifth edition. Oxford University Press, 2007
- Todar K. Bacterial resistance to antibiotics. Todar's online textbook on bacteriology, 2008. Available from: http://www.textbookofbacteriology.net [Cited 20 Dec 2008]
- Brigham N. World of microbiology and immunology. Thomson Gale Press, 2006;2
- Zahnel G, Hoban D, Harding G. The post-antibiotic effect: a review of in vitro and in vivo data. Ann Pharmacother 1991;25:153-63
- Formulation boosts antibiotic efficacy. Decision News Media, 2004. Available from: http://www.in-pharmatechnologist.com/ Materials-Formulation/ Formulation-boosts-antibiotic-efficacy [Cited 3 Jan 2009]
- Forward-looking statements form 10-K. Middlebrook Pharmaceuticals Business Inc., 2008. Available from: http://google.brand.edgar-online.com [cited 5 Jan 2009]
- Michiu K. Multiple-delayed release formulation approach for the treatment of methicillin-resistant Staphylococcus aureus. Exp Opin Ther Pat 2008;18:1313-9
- Sun H, Lee S, Banevicius M, et al. Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model. J Antimicrob Chemother 2005;56:559-65
- New antibiotics developments are on the horizon. Middlebrook Pharmaceuticals, 2007. Available from: http://www.advancispharm.com/PIPE_new_antibiotics. [Last accessed 8 January 2009]
- Magruder P, Barclay B, Wong P, Theeuwes F. Composition comprising salbutamol. US4751071; 1988
- Gazziranga A, Giordano F. Delayed release systems (DRS) based on retarding swellable hydrophilic coating. Proc 12 Pharmaceutical International Technology Conference 1993;1:400-8
- Gazziranga A, Iamatrino P, Sangalli M. Oral delayed release system for colon specific delivery. Int J Pharm 1994;108:77-83
- Conte U, Maggi L. Modulation of the dissolution profiles from Geomatrix multi-layer matrix tablets containing drugs of different solubility. Biomaterials 1996;17:889-96
- Conte U, Maggi L. Geomatrix tablets for the pulsatile release of drugs. Proc Int Symp Control Release Bioactive Mater 1997;24:291-2
- Conte U, Maggi L, La Manna. Pharmaceutical tablet capable of releasing the active ingredients contained therein at subsequent times. US5650169; 1997
- Pozzi F, Furlani P, Gazziranga A, et al. The time clock system: a new oral dosage form for fast and complete release of drug after predetermined lag time. J Control Release 1994;31:99-108
- Held K, Marolf T, Erni W. Principle and development of a tablet formulation with pulsatile drug delivery after a controlled and pH dependent latency period. Acta Pharm Technol 1990;36:38s
- Stevens HNE. Chronopharmaceutical drug delivery. J Pharm Pharmacol 1998;50:s5
- Stevens HNE, Chariot M, Arnold F, Lewis GA. Sustained release pharmaceutical compositions of diltiazem. US5112621; 1992
- Ueda Y, Hata T, Yamaguchi H, et al. Time-controlled explosion systems. US4871549; 1989
- Chen CM. Pulsatile particles drug delivery system. US5260069; 1993
- Rashid A. Dispensing device. EP0384642; 1990
- Crison JR, Siersma PR, Taylor MD, Amidon GL. Programmable oral release technology PORT system: a novel dosage form for time and site specific oral drug delivery. Proc Int Symp Control Release Bioactive Mater 1995;22:278-79
- McNeill ME, Rashid A, Stevens HNE. Drug dispensing device. GB2230442; 1993
- Wong PSL, Theeuwes F, Larsen SD. Osmotic device for delayed delivery of agent. US5312388; 1994
- Ross AC, MacRae RJ, Walther M, Stevens HNE. Chronopharmaceutical drug delivery from a pulsatile capsule device based on programmable erosion. J Pharm Pharmacol 2000;52:903-9
- Niwa K, Takaya T, Morimoto T, Takada K. Preparation and evaluation of a time controlled release capsule made of ethyl cellulose for colon delivery of drugs. J Drug Target 1995;3:83-9
- Stevens HNE, Ross AC, Johnson JR. The hydrophilic-sandwich (HS) capsule: a convenient time delayed oral probe device. J Pharm Pharmacol 2000;52:s41
- Flanner H, Treasy D, Ebrahim S, et al. Gastric release pulse system for drug delivery. WO079082; 2007
- Flanner H, Treasy D, Ebrahim S, et al. Gastric release pulse system for drug delivery. US0154547; 2007
- Klein S, Stein J, Dressman J. Site specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in vitro release model. J Pharm Pharmacol 2005;57:709-19
- Lerner I, Flashner M, Penhasi A. Immediate release gastrointestinal drug delivery system. US6531152B1; 2003
- Huyghebaert N, Vermeire A, Remon JP. In vitro evaluation of coating polymers for enteric coating and human ileal targeting. Int J Pharm 2005;298:26-37
- Chang R, Shah N. Two or more enteric materials to regulate drug release. WO062557; 2004
- Gupta V, Beckert T, Price J. A novel pH and time-based multi-unit potential colonic drug delivery system. Int J Pharm 2001;213:83-91
- Kastra W, Cima M, Palazzolo B, et al. Oral dosage form by three dimensional printing. Proc Int Symp Control Release Bioactive Mater 1998;25:760-61
- Kastra W, Rowe A, Teung P, Cima M. Pulsatory oral drug delivery devices fabricated by three-dimensional printing. Proc Int Symp Control Release Bioactive Mater 1999;26:569-70
- Li Y, Zhu J. Modulation of combined release behaviors from a novel ‘tablets in capsule system’. J Control Release 2004;95:381-389
- Li Y, Zhu J, Gong W. A novel system for three-pulse drug release based on ‘tablets in capsule’ device. Int J Pharm 2007;352:159-64
- El-Mallah Y, Nazzal S. Novel use of Eudragit NE30D/Eugragit L30D55 blend as functional coating materials in time delayed release application. Int J Pharm 2008;357:219-27
- Ibrahim K, Gunderson R, Laurie B, et al. Pharmacodynamics of pulse dosing versis standard dosing: in vitro metronidazole activity against Bacteroides fragilis and B. theteiotamicron. Antimicrobial Agents Chemother 2004;48:4195-9
- Stupak E, Cho P. Controlled release flutamide composition. US5162117; 1993
- Chen C. Pulsatile particles drug delivery system. US5260069; 2001
- Lerner I, Flashner M. Immediate release gastrointestinal drug delivery system. WO9918938; 1999
- Percel P, Vishnupad K, Krishna S. Timed Pulsatile drug delivery systems. US7048945; 2003
- Marchetti A, Magar R, Lau H, et al. Pharmacotherapies for attention-deficit/ hyperactivity disorder: expected cost analysis. Clin Ther 2001;23:1904-21
- Conte U, Colombo P, La Manna A, et al. A new ibuprofen pulsed release oral dosage form. Drug Dev Ind Pharm 1989;15:2583-96
- MiddleBrook Pharmaceuticals to Launch Moxatag March 2009. Logistics Online, 2009. Available from: http://www.logisticsonline.com/article.mvv. [Last accessed 26 January 2009]
- Moxatag Consumer Information. Drug information online, 2009. Available from: http://www.drugs.com/moxatag.html. [Last accessed 20 January 2009]
- Highlights of prescribing information. MOXATAG™ (amoxicillin extended-release) Tablets, 2009. Available from: www.fda.gov/cder/foi/label/2008/050813lbl.pdf. [Last accessed 21 January 2009]
- Adis International. Amoxicillin Pulsatile – MiddleBrook: APC 111, APC-111, PULSYS-Enhanced Amoxicillin. Drugs R D 2007;8:395-9
- FDA Approves MiddleBrook's Moxatag – Amoxicillin PULSYS - for Pharyngitis/Tonsillitis in Adolescents and Adults. Drugs information online, 2008. Available from: http://www.drugs.com/newdrugs/fda-approves-middlebrook-s-moxatag-amoxicillin-pulsys-pharyngitis-tonsillitis-adolescents-adults-824.html. [Last accessed 9 January 2009]
- A breakthrough in anti-infective therapy. Middlebrook Pharmaceuticals, 2008. Available from: http://www.middlebrookpharma.com/BREAKTHROUGH_technology/NOVEL_infectious.aspx. [Last accessed 24 January 2009]
- A discovery that signals fundamental change. Middlebrook Pharmaceuticals, 2008. Available from: http://www.middlebrookpharma.com/BREAKTHROUGH_technology/ default.aspx. [Last accessed 24 January 2009]
- Keflex (Cephalexin, USP) products. Middlebrook Pharmaceuticals, 2008. Available from: http://www.middlebrookpharma.com/PRODUCTS_antibiotics/ KEFLEX_antibiotics.aspx. [Last accessed 25 January 2009]
- The Middlebrook Pharmaceuticals, Inc Patent Strategy. Middlebrook Pharmaceuticals, 2008. Available from: http://www.middlebrookpharma.com/BREAKTHROUGH_technology/ patents.aspx. [Last accessed 25 January 2009]
- New antibiotics developments are on the horizon. Middlebrook Pharmaceuticals, 2008. Available from: http://www.middlebrookpharma.com/PIPE_new_antibiotics/default.aspx. [Last accessed 25 January 2009]
- Cha R, Rybak M. Pulsatile delivery of amoxicillin against Streptococcus pneumoniae. J Antimicrob Chemother 2004;54:1064-71
- A proven difference. Middlebrook Pharmaceuticals, 2008. Available from: http://www.middlebrookpharma.com/BREAKTHROUGH_technology/preclinical.aspx. [Last accessed 20 January 2009]
- Redefining Infectious Disease therapy. The PULSYS technology platform. Middlebrook Pharmaceuticals, 2008. Available from: www.advancispharm.com/pdf/pulsysproducts.pdf. [Last accessed 15 January 2009]
- Our proprietary drug delivery technology PULSYS™. Middlebrook Pharmaceuticals, 2008. Available from: http://www.middlebrookpharma.com/BREAKTHROUGH_technology/TECH_drug_delivery.aspx. [Last accessed 24 January 2009]
- Advancis Pharmaceutical Announces FDA Acceptance of Amoxicillin PULSYS NDA. Life Sciences world, 2008. Available from: http://www.lifesciencesworld.com/news/view/33928. [Last accessed 9 January 2009]
- Newly approved drug therapies (977) Moxatag (amoxicillin). Middlebrook Pharmaceuticals, 2008. Available from: http://www.centerwatch.com/ drug-information/fda-approvals/drug-details.aspx?DrugID=977. [Last accessed 11 January 2009]
- Lan A, Colford J. The impact of dosing frequency on the efficacy of 10-day penicillin or amoxicillin therapy for streptococcal tonsillopharyngitis: A Meta-analysis. Pediatrics 2000;105:e19
- Redesigning drugs to enhance performance. Verticaltalk. Pharma Focus Asia, 2008. Available from: http://www.pharmafocusasia.com/manufacturing/redesigning_drugs.htm. [Last accessed 5 January 2009]
- Flanner H, Treacy D, Beth B, et al. Modified release amoxicillin products. US20080132478; 2008
- Rudnic E, Isbister J, Donald J, et al. Multiple delayed released antibiotic product, use and formulation thereof. US7025989; 2006
- See how PULSYS works. Middlebrook Pharmaceuticals, 2008. Available from: http://www.middlebrookpharma.com/BREAKTHROUGH_technology/ default.aspx. [Last accessed 18 January 2009]
- Rudnic E, Isbister J, Treasy J, et al. Antiviral product, use and formulation thereof. US6541014; 2003
- Moxatag approval a crucial first for Middlebrook. Breaking news on pharmaceutical technology, 2008. Available from: http://www.in-pharmatechnologist.com/Materials-Formulation/Moxatag-approval-a-crucial-first-for-MiddleBrook. [Last accessed 20 January 2009]